Keyphrases
Clinical Trials
100%
Drug Development
100%
Risk Outcomes
100%
Patient Outcomes
100%
Patient Benefit
100%
Risk-benefit
100%
Patient Risk
100%
Lenvatinib
100%
FDA-approved Drugs
66%
Adverse Events
33%
Pharmaceutical Companies
16%
PubMed
16%
MEDLINE
16%
Embase
16%
Adverse Effects
16%
Cancer Diagnosis
16%
Solid Tumors
16%
Number of Trials
16%
Cochrane
16%
Overall Survival
16%
Progression-free Survival
16%
Drug Efficacy
16%
Trial Characteristics
16%
Objective Response Rate
16%
Cost Reduction
16%
Clinical Trial Results
16%
Risk-benefit Ratio
16%
FDA Indications
16%
Approved Indication
16%
Therapeutic Benefits
16%
Adult Participants
16%
Adverse Event Data
16%
Therapeutic Focus
16%
Cancer Drugs
16%
Solid Cancer
16%
Survival Response
16%
Clinical Trial Participant
16%
Novel Indications
16%
Cancer Drug Therapy
16%
Drug Promotion
16%
Marketing Strategy
16%
Sunitinib
16%
Drug Development Strategy
16%
Non-randomized Clinical Trial
16%
Imatinib
16%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Drug Development
100%
Lenvatinib
100%
Malignant Neoplasm
83%
Adverse Event
66%
Pharmacotherapy
16%
Randomized Clinical Trial
16%
Progression Free Survival
16%
Overall Survival
16%
Solid Malignant Neoplasm
16%
Clinical Trial Results
16%
Sunitinib
16%
Imatinib
16%